

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

## When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member's contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider a single<sup>1</sup> course of enhanced external counterpulsation (EECP) to be **eligible for coverage**\*\* when the criteria below are met:

- Disabling, chronic, stable angina (defined as Class III or Class IV Canadian Cardiovascular Society Classification angina or equivalent, see Policy guidelines); and
- Refractory to optimal medical therapy and not readily amenable to surgical intervention such as percutaneous transluminal coronary angioplasty (PTCA) or cardiac bypass due to **any** of the following:
  - Condition is inoperable; or
  - High risk of operative complications or postoperative failure; or
  - Coronary anatomy is not readily amenable to such procedures; and
- None of the comorbid conditions or contraindications that would result in excessive risk are present, including but not limited to the following:
  - Aortic insufficiency (regurgitation might prevent diastolic augmentation); or,
  - Uncontrolled arrhythmias such as atrial fibrillation, atrial flutter, ventricular tachycardia, sustained tachycardia with heart rate > 120 beats per minute, and frequent premature ventricular beats (might interfere with the device's triggering mechanism); or
  - $\circ$  Uncontrolled bleeding diatheses (INR > 2); or
  - Severe or decompensated heart failure; or
  - Deep vein thrombosis, varicosities, or stasis ulcers; or
  - Severe peripheral arterial disease or phlebitis (increased risk of thromboembolus); or
  - Severe hypertension with BP > 180/110 mmHg (treatment could produce diastolic blood pressure above acceptable limits); or
  - o Stroke.

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross Blue Shield Association. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

#### Note:

<sup>1</sup>A single course of treatment consists of a total of 35 hours of enhanced external counterpulsation (EECP); treatment is administered for one to two hours daily, 5 days a week, for approximately  $3\frac{1}{2}$  to 7 weeks.

Based on review of available data, the Company may consider a repeat course of enhanced external counterpulsation (EECP) therapy in individuals who met the criteria in section above, have chronic stable angina and who have objectively demonstrated a response to EECP to be **eligible for coverage**\*\*. This would include those individuals who demonstrate one or more of the following:

- Early improvement in radionuclide stress perfusion imaging compared to a pre-EECP baseline; **or**
- Reduction in antianginal medication use; or
- Improvement in exercise tolerance.

## When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

The use of enhanced external counterpulsation (EECP) when the above patient selection criteria are not met and for all other indications is considered to be **investigational.**\*

## **Policy Guidelines**

Canadian Cardiovascular Society Score: This organization defines anginal classes as follows:

- Class I Ordinary physical activity (e.g., walking and climbing stairs) does not cause angina. Angina with strenuous or rapid prolonged exertion at work or recreation.
- Class II Slight limitation of ordinary activity. Angina with walking or climbing stairs rapidly, walking uphill, walking more than 2 blocks on the level and climbing more than 1 flight of stairs at a normal pace.
- Class III Marked limitation of ordinary physical activity. Angina with walking 1 to 2 blocks on the level and climbing 1 flight in normal conditions.
- Class IV Inability to carry on physical activity without discomfort. Anginal syndrome may be present at rest.

## **Background/Overview**

Enhanced external counterpulsation (EECP) uses timed, sequential inflation of pressure cuffs on the calves, thighs, and buttocks to augment diastolic pressure, decrease left ventricular afterload, and increase venous return. The proposed mechanism of action is the augmentation of diastolic pressure by displacement of a volume of blood backward into the coronary arteries during diastole when the heart is in a state of relaxation and resistance in the coronary arteries is at a minimum. The resulting

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

increase in coronary artery perfusion pressure may enhance coronary collateral development or increase flow through existing collaterals. Also, when the left ventricular contracts, it faces reduced aortic counterpressure, because the counterpulsation has somewhat emptied the aorta. EECP has been primarily investigated as a treatment for chronic stable angina.

Intra-aortic balloon counterpulsation is a more familiar, invasive form of counterpulsation that is used as a method of temporary circulatory assistance for the ischemic heart, often after acute myocardial infarction. In contrast, EECP is thought to provide a permanent effect on the heart by enhancing the coronary collateral development. A full course of therapy usually consists of 35 one-hour treatments, which may be offered once or twice daily, usually 5 days a week. The multiple components of the procedure include the use of the device itself, finger plethysmography to follow the blood flow, continuous electrocardiograms to trigger inflation and deflation, and optional use of pulse oximetry to measure oxygen saturation before and after treatment.

While EECP has been primarily researched as a treatment of chronic stable angina, it has also been used in individuals with congestive heart failure.

*Note:* This policy only addresses the outpatient use of EECP, i.e., for the treatment of chronic stable angina or congestive heart failure. This policy does not address its use for unstable angina pectoris, acute myocardial infarction or cardiogenic shock.

## FDA or Other Governmental Regulatory Approval

#### U.S. Food and Drug Administration (FDA)

A variety of EECP devices have been cleared for marketing by the FDA through the 510(k) process. Examples of EECP devices with FDA clearance are outlined in Table 1. Food and Drug Administration product code: DRN.

 Table 1. FDA-Cleared EECP Devices

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

| Device   | Manufacturer                   | Cleared     | Indications  |
|--|--------------------------------|-------------|--|
| External<br>Counterpulsation<br>System                     | Vamed<br>Medical<br>Instrument | Sep<br>2019 | <ul> <li>Chronic stable angina refractory to optimal anti-anginal medical therapy and without options for revascularization</li> <li>In healthy patients to improve vasodilation, increase Vo2, and increase blood flow</li> </ul> |
| Pure Flow<br>External<br>Counter-<br>Pulsation Device      | Xtreem Pulse                   | May<br>2018 | <ul> <li>Chronic stable angina refractory to optimal anti-anginal medical therapy and without options for revascularization</li> <li>In healthy patients to improve vasodilation, increase Vo2, and increase blood flow</li> </ul> |
| Renew® NCP-5<br>External<br>Counterpulsation<br>System     | Renew Group                    | Dec<br>2015 | <ul> <li>Chronic stable angina refractory to optimal anti-anginal medical therapy and without options for revascularization</li> <li>In healthy patients to improve vasodilation, increase Vo2, and increase blood flow</li> </ul> |
| ECP Health<br>System Model                                 | ECP Health                     | Aug<br>2005 | <ul> <li>Stable or unstable angina pectoris</li> <li>Acute myocardial infarction</li> <li>Cardiogenic shock</li> <li>Congestive heart failure</li> </ul>   |
| CardiAssist <sup>™</sup><br>Counter<br>Pulsation<br>System | Cardiomedics                   | Mar<br>2005 | • Ischemic heart disease by increasing<br>perfusion during diastole in people with<br>chronic angina pectoris, congestive heart<br>failure, myocardial infarction, and<br>cardiogenic shock  |
| ACS Model<br>NCP-2 External                                | Applied<br>Cardiac<br>Systems  | Aug<br>2004 | <ul><li>Stable or unstable angina pectoris</li><li>Acute myocardial infarction</li></ul>   |

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

| Device  | Manufacturer                   | Cleared     | Indications  |
|---|--------------------------------|-------------|--|
| External<br>Counterpulsation<br>System                | Vamed<br>Medical<br>Instrument | Sep<br>2019 | <ul> <li>Chronic stable angina refractory to optimal anti-anginal medical therapy and without options for revascularization</li> <li>In healthy patients to improve vasodilation, increase Vo2, and increase blood flow</li> </ul> |
| Pure Flow<br>External<br>Counter-<br>Pulsation Device | Xtreem Pulse                   | May<br>2018 | <ul> <li>Chronic stable angina refractory to optimal anti-anginal medical therapy and without options for revascularization</li> <li>In healthy patients to improve vasodilation, increase Vo2, and increase blood flow</li> </ul> |
| Counterpulsation<br>Device                            |                                |             | <ul><li>Cardiogenic shock</li><li>Congestive heart failure</li></ul>   |
| EECP® Therapy<br>System                               | Vasomedical                    | Mar<br>2004 | <ul> <li>Stable or unstable angina pectoris</li> <li>Acute myocardial infarction</li> <li>Cardiogenic shock</li> <li>Congestive heart failure</li> </ul>   |

EECP: enhanced external counterpulsation; FDA: Food and Drug Administration; Vo2: oxygen consumption.

## **Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

The use of EECP for the treatment of disabling, chronic, stable disabling angina in individuals who are not suitable candidates for surgical intervention or who have failed surgical intervention has been established in the medical evidence. Several large-scale prospective studies evaluating the efficacy

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

of EECP in individuals with chronic stable angina demonstrate significant improvements in anginal symptoms, myocardial perfusion and output. One randomized, sham-controlled trial demonstrated significant improvement at 12 months in individuals who underwent a single 35-hour course of EEPC. In this study treatment-group, individuals reported significant improvements compared to sham treated individuals in all nine quality of life scales included on the Medical Outcomes Study SF-36 health survey, including the activities of daily living, ability to work, bodily pain and others.

EECP has also been studied for the treatment of congestive heart failure. In 2002, Soran and colleagues reported on a feasibility study of EECP as a treatment for congestive heart failure in 26 individuals. In this uncontrolled study, the individuals were treated with 35 daily, one-hour sessions and followed for six months after completion of the course of therapy. The study suggests that the treatment was safe and well tolerated. Based in part on the results of this study, a larger, randomized study has been launched, the PEECH trial (Prospective Evaluation of EECP in Congestive Heart Failure). Results of this trial have not yet been published.

The evidence regarding the use of EECP for other indications, including other anginal or cardiac conditions, such as including non-disabling stable angina or unstable angina is currently insufficient to allow conclusions to be made.

Studies of EECP in angina individuals with severe left ventricular dysfunction suggest that improvement in anginal symptoms, as well as quality of life, are consistent, independent of degree of ventricular dysfunction, and sustainable for up to two years) Similar results were noted after one year in an observational study published in 2005 of 746 angina individuals with either systolic or diastolic dysfunction who received EECP for their angina.

## **Supplemental Information**

#### **Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 3 academic medical centers while this policy was under review in 2008 and 2010. Reviewers agreed with the conclusion that enhanced external counterpulsation was investigational. Some reviewers commented on the potential use of enhanced external counterpulsation in those with angina not amenable to surgical interventions.

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

#### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

# Joint Guidelines from the American College of Cardiology Foundation, American Heart Association et al

In 2012, the American College of Cardiology Foundation, American Heart Association, and 5 other medical societies published joint guidelines that recommended: "[patients with stable ischemic heart disease who indicate for enhanced external counterpulsation (EECP)] may be considered for relief of refractory angina." This recommendation was class IIb, based on level B evidence (ie, the efficacy of the intervention is not well established, and further studies would be helpful).

In 2014, the American College of Cardiology Foundation and American Heart Association updated these joint guidelines. Based on this review, the groups did not change their recommendation on EECP from the 2012 guidelines.

The 2022 American College of Cardiology Foundation, American Heart Association, and Heart Failure Society of America guidelines on the management of heart failure do not address EECP.

#### U.S. Preventive Services Task Force Recommendations

Not applicable.

#### **Medicare National Coverage**

Medicare has published a national coverage decision on EECP that mandates coverage for the following indications:

"Coverage is provided for the use of ECP [external counterpulsation] for patients who have been diagnosed with disabling angina who, in the opinion of a cardiologist or cardiothoracic surgeon, are not readily amenable to surgical intervention, such as percutaneous transluminal coronary angioplasty or cardiac bypass because: 1) Their condition is inoperable, or at high risk of operative complications or post-operative failure; 2) Their coronary anatomy is not readily amendable to such procedures; or 3) They have co-morbid states which create excessive risk."

Medicare's coverage decision also noted that while the U.S. Food and Drug Administration has cleared EECP "for use in treating a variety of cardiac conditions, including stable or unstable angina pectoris, acute myocardial infarction and cardiogenic shock, the use of this device to treat cardiac conditions other than stable angina pectoris is not covered...."

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

#### **Ongoing and Unpublished Clinical Trials**

Some currently unpublished trials that might influence this review are listed in Table 2.

| Table 2 | . Summary | of Key | Trials |
|---------|-----------|--------|--------|
|---------|-----------|--------|--------|

| NCT No.     | Trial Name   | Planned<br>Enrollment | Completion<br>Date |
|-------------|--|-----------------------|--------------------|
| Ongoing     |  |                       |                    |
| NCT05913778 | Long-term Effects of Enhanced External<br>Counterpulsation on the Structural and Functional<br>State of Blood Vessels in Patients With Coronary<br>Heart Disease and Chronic Heart Failure | 100 (actual)          | Dec 2024           |

NCT: national clinical trial.

### **References**

- 1. Anthem clinical UM Guideline. Enhanced External Counterpulsation in the Outpatient Setting. Guideline # CG-MED-86. Publish Date 01/30/2025. Last Reviewed Date 11/14/2024.
- Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. Jun 1999; 33(7): 1833-40. PMID 10362181
- 3. Arora RR, Chou TM, Jain D, et al. Effects of enhanced external counterpulsation on Health-Related Quality of Life continue 12 months after treatment: a substudy of the Multicenter Study of Enhanced External Counterpulsation. J Investig Med. Jan 2002; 50(1): 25-32. PMID 11813825
- 4. Bondesson SM, Edvinsson ML, Pettersson T, et al. Reduced peripheral vascular reactivity in refractory angina pectoris: Effect of enhanced external counterpulsation. J Geriatr Cardiol. Dec 2011; 8(4): 215-23. PMID 22783308
- 5. Gloekler S, Meier P, de Marchi SF, et al. Coronary collateral growth by external counterpulsation: a randomised controlled trial. Heart. Feb 2010; 96(3): 202-7. PMID 19897461
- Buschmann EE, Utz W, Pagonas N, et al. Improvement of fractional flow reserve and collateral flow by treatment with external counterpulsation (Art.Net.-2 Trial). Eur J Clin Invest. Oct 2009; 39(10): 866-75. PMID 19572918
- 7. Braith RW, Conti CR, Nichols WW, et al. Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. Circulation. Oct 19 2010; 122(16): 1612-20. PMID 20921442
- Casey DP, Beck DT, Nichols WW, et al. Effects of enhanced external counterpulsation on arterial stiffness and myocardial oxygen demand in patients with chronic angina pectoris. Am J Cardiol. May 15 2011; 107(10): 1466-72. PMID 21420062

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

- Shakouri SK, Razavi Z, Eslamian F, et al. Effect of Enhanced External Counterpulsation and Cardiac Rehabilitation on Quality of Life, Plasma Nitric Oxide, Endothelin 1 and High Sensitive CRP in Patients With Coronary Artery Disease: A Pilot Study. Ann Rehabil Med. Apr 2015; 39(2): 191-8. PMID 25932415
- Holubkov R, Kennard ED, Foris JM, et al. Comparison of patients undergoing enhanced external counterpulsation and percutaneous coronary intervention for stable angina pectoris. Am J Cardiol. May 15 2002; 89(10): 1182-6. PMID 12008172
- Shechter M, Matetzky S, Feinberg MS, et al. External counterpulsation therapy improves endothelial function in patients with refractory angina pectoris. J Am Coll Cardiol. Dec 17 2003; 42(12): 2090-5. PMID 14680732
- 12. Feldman AM, Silver MA, Francis GS, et al. Treating heart failure with enhanced external counterpulsation (EECP): design of the Prospective Evaluation of EECP in Heart Failure (PEECH) trial. J Card Fail. Apr 2005; 11(3): 240-5. PMID 15812754
- Feldman AM, Silver MA, Francis GS, et al. Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. Sep 19 2006; 48(6): 1198-205. PMID 16979005
- 14. Abbottsmith CW, Chung ES, Varricchione T, et al. Enhanced external counterpulsation improves exercise duration and peak oxygen consumption in older patients with heart failure: a subgroup analysis of the PEECH trial. Congest Heart Fail. 2006; 12(6): 307-11. PMID 17170583
- 15. Rampengan SH, Prihartono J, Siagian M, et al. The Effect of Enhanced External Counterpulsation Therapy and Improvement of Functional Capacity in Chronic Heart Failure patients: a Randomized Clinical Trial. Acta Med Indones. Oct 2015; 47(4): 275-82. PMID 26932695
- 16. Belenkov YN, Lishuta AS, Slepova OA, et al. The EXCEL Study: Long-term Observation of the Effectiveness of Drug and Non-drug Rehabilitation in Patients with Ischemic Heart Failure. Kardiologiia. Jan 31 2024; 64(1): 14-24. PMID 38323440
- 17. Soran O, Kennard ED, Kelsey SF, et al. Enhanced external counterpulsation as treatment for chronic angina in patients with left ventricular dysfunction: a report from the International EECP Patient Registry (IEPR). Congest Heart Fail. 2002; 8(6): 297-302. PMID 12461318
- 18. Lawson WE, Kennard ED, Holubkov R, et al. Benefit and safety of enhanced external counterpulsation in treating coronary artery disease patients with a history of congestive heart failure. Cardiology. 2001; 96(2): 78-84. PMID 11740136
- 19. Lawson WE, Silver MA, Hui JC, et al. Angina patients with diastolic versus systolic heart failure demonstrate comparable immediate and one-year benefit from enhanced external counterpulsation. J Card Fail. Feb 2005; 11(1): 61-6. PMID 15704066
- 20. Vijayaraghavan K, Santora L, Kahn J, et al. New graduated pressure regimen for external counterpulsation reduces mortality and improves outcomes in congestive heart failure: a report from the Cardiomedics External Counterpulsation Patient Registry. Congest Heart Fail. 2005; 11(3): 147-52. PMID 15947536

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

- 21. Soran O, Fleishman B, Demarco T, et al. Enhanced external counterpulsation in patients with heart failure: a multicenter feasibility study. Congest Heart Fail. 2002; 8(4): 204-8, 227. PMID 12147943
- 22. McKenna C, McDaid C, Suekarran S, et al. Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis. Health Technol Assess. Apr 2009; 13(24): iii-iv, ix-xi, 1-90. PMID 19409154
- 23. Lin JC, Song S, Ng SM, et al. Interventions for acute non-arteritic central retinal artery occlusion. Cochrane Database Syst Rev. Jan 30 2023; 1(1): CD001989. PMID 36715340
- 24. Werner D, Michalk F, Harazny J, et al. Accelerated reperfusion of poorly perfused retinal areas in central retinal artery occlusion and branch retinal artery occlusion after a short treatment with enhanced external counterpulsation. Retina. Aug 2004; 24(4): 541-7. PMID 15300074
- 25. Lawson WE, Hui JC, Kennard ED, et al. Effect of enhanced external counterpulsation on medically refractory angina patients with erectile dysfunction. Int J Clin Pract. May 2007; 61(5): 757-62. PMID 17493089
- 26. Han JH, Leung TW, Lam WW, et al. Preliminary findings of external counterpulsation for ischemic stroke patient with large artery occlusive disease. Stroke. Apr 2008; 39(4): 1340-3. PMID 18309160
- 27. Lin S, Liu M, Wu B, et al. External counterpulsation for acute ischaemic stroke. Cochrane Database Syst Rev. Jan 18 2012; 1: CD009264. PMID 22259001
- 28. Sardina PD, Martin JS, Avery JC, et al. Enhanced external counterpulsation (EECP) improves biomarkers of glycemic control in patients with non-insulin-dependent type II diabetes mellitus for up to 3 months following treatment. Acta Diabetol. Oct 2016; 53(5): 745-52. PMID 27179825
- 29. Sardina PD, Martin JS, Dzieza WK, et al. Enhanced external counterpulsation (EECP) decreases advanced glycation end products and proinflammatory cytokines in patients with non-insulin-dependent type II diabetes mellitus for up to 6 months following treatment. Acta Diabetol. Oct 2016; 53(5): 753-60. PMID 27278477
- 30. Nagendra L, Dutta D, Sharma M, et al. Impact of Enhanced External Counter-pulsation Therapy on Glycaemic Control in People With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. touchREV Endocrinol. Nov 2023; 19(2): 9-15. PMID 38187074
- 31. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. Dec 18 2012; 60(24): e44-e164. PMID 23182125
- 32. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. Nov 04 2014; 64(18): 1929-49. PMID 25077860

- 33. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. May 03 2022; 79(17): e263-e421. PMID 35379503
- 34. Center for Medicare & Medicaid Services (CMS). National Coverage Determination for external counterpulsation (ECP) therapy for severe angina (20.20). 2006; https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=97&ncdver=2

## **Policy History**

| Original Effectiv | ve Date: 11/12/2001   |  |  |
|-------------------|---|--|--|
| Current Effectiv  | e Date: 06/01/2025  |  |  |
| 10/18/2001        | Medical Policy Committee review   |  |  |
| 11/12/2001        | Managed Care Advisory Council approval  |  |  |
| 06/24/2002        | Format revision. No substance change to policy.                                 |  |  |
| 10/21/2003        | Medical Policy Committee review Format revision. No substance change to policy. |  |  |
| 01/26/2004        | Managed Care Advisory Council approval  |  |  |
| 01/04/2005        | Medical Director review   |  |  |
| 01/18/2005        | Medical Policy committee review   |  |  |
| 01/31/2005        | Managed Care Advisory council approval. Investigational policy added            |  |  |
| 05/03/2006        | Medical Director review   |  |  |
| 06/21/2006        | Medical Policy Committee approval. Format revision, including, addition of FDA  |  |  |
|                   | and or other governmental regulatory approval and rationale/source. Coverage    |  |  |
|                   | eligibility unchanged.  |  |  |
| 05/02/2007        | Medical Director review   |  |  |
| 05/23/2007        | Medical Policy Committee approval. No change to coverage eligibility.           |  |  |
| 05/07/2008        | Medical Director review   |  |  |
| 05/21/2008        | Medical Policy Committee approval. No change to coverage eligibility.           |  |  |
| 05/07/2009        | Medical Director review   |  |  |
| 05/20/2009        | Medical Policy Committee approval. No change to coverage eligibility.           |  |  |
| 06/03/2010        | Medical Policy Committee review   |  |  |
| 06/16/2010        | Medical Policy Implementation Committee approval. No change to coverage         |  |  |
|                   | eligibility.  |  |  |
| 05/05/2011        | Medical Policy Committee review   |  |  |
| 05/18/2011        | Medical Policy Implementation Committee approval. No change to coverage         |  |  |
|                   | eligibility.  |  |  |
| 05/03/2012        | Medical Policy Committee review   |  |  |
| 05/16/2012        | Medical Policy Implementation Committee approval. No change to coverage         |  |  |
|                   | eligibility.  |  |  |

| Policy # 0003     | 6   |  |  |
|-------------------|---|--|--|
| Original Effectiv | ve Date: 11/12/2001   |  |  |
| Current Effectiv  | e Date: 06/01/2025  |  |  |
|                   |   |  |  |
| 05/02/2013        | Medical Policy Committee review   |  |  |
| 05/22/2013        | Medical Policy Implementation Committee approval. No change to coverage         |  |  |
|                   | eligibility.  |  |  |
| 05/01/2014        | Medical Policy Committee review   |  |  |
| 05/21/2014        | Medical Policy Implementation Committee approval. No change to coverage         |  |  |
|                   | eligibility.  |  |  |
| 05/07/2015        | Medical Policy Committee review   |  |  |
| 05/20/2015        | Medical Policy Implementation Committee approval. No change to coverage         |  |  |
|                   | eligibility.  |  |  |
| 05/05/2016        | Medical Policy Committee review   |  |  |
| 05/18/2016        | Medical Policy Implementation Committee approval. No change to coverage         |  |  |
| 01/01/0015        | eligibility.  |  |  |
| 01/01/2017        | Coding update: Removing ICD-9 Diagnosis Codes                                   |  |  |
| 05/04/2017        | Medical Policy Committee review   |  |  |
| 05/1//201/        | Medical Policy Implementation Committee approval. No change to coverage         |  |  |
| 05/02/2019        | eligibility.  |  |  |
| 05/05/2018        | Medical Policy Commute review   |  |  |
| 03/16/2018        | Medical Policy Implementation Committee approval. Criteria revised to approve a |  |  |
| 05/02/2010        | Medical Policy Committee review   |  |  |
| 05/15/2019        | Medical Policy Implementation Committee approval. No change to coverage         |  |  |
| 05/07/2020        | Medical Policy Implementation Committee approval. No change to coverage.        |  |  |
| 05/13/2020        | Medical Policy Implementation Committee approval Coverage eligibility           |  |  |
| 03/13/2020        | unchanged   |  |  |
| 05/06/2021        | Medical Policy Committee review   |  |  |
| 05/12/2021        | Medical Policy Implementation Committee approval Coverage eligibility           |  |  |
| 00/12/2021        | unchanged Undated FDA   |  |  |
| 05/05/2022        | Medical Policy Committee review   |  |  |
| 05/11/2022        | Medical Policy Implementation Committee approval. Coverage eligibility          |  |  |
|                   | unchanged.  |  |  |
| 05/04/2023        | Medical Policy Committee review   |  |  |
| 05/10/2023        | Medical Policy Implementation Committee approval. Patient selection completely  |  |  |
|                   | revised. Added investigational denial statement for when criteria are not met.  |  |  |
| 05/02/2024        | Medical Policy Committee review   |  |  |
| 05/08/2024        | Medical Policy Implementation Committee approval. No change to coverage.        |  |  |
| 05/01/2025        | Medical Policy Committee review   |  |  |
| 05/13/2025        | Medical Policy Implementation Committee approval. Coverage eligibility          |  |  |
|                   | unchanged.  |  |  |
| Next Scheduled    | Review Date: 05/2026  |  |  |

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

## **Coding**

The five character codes included in the Louisiana Blue Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology  $(CPT^{\$})^{\ddagger}$ , copyright 2024 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Louisiana Blue Medical Policy Coverage Guidelines is with Louisiana Blue and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Louisiana Blue Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Louisiana Blue Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

| Code Type        | Code                  |
|------------------|-----------------------|
| СРТ              | 92971                 |
| HCPCS            | G0166                 |
| ICD-10 Diagnosis | All Related Diagnoses |

\*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or

Policy # 00036 Original Effective Date: 11/12/2001 Current Effective Date: 06/01/2025

diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

- 1. Consultation with technology evaluation center(s);
- 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
- 3. Reference to federal regulations.
- \*\*Medically Necessary (or "Medical Necessity") Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:
  - A. In accordance with nationally accepted standards of medical practice;
  - B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
  - C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

**NOTICE:** If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

**NOTICE:** Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.